医学
心理干预
系统回顾
荟萃分析
药方
比尔斯标准
不利影响
梅德林
挪威语
药物反应
药品
重症监护医学
多药
急诊医学
内科学
药理学
精神科
法学
哲学
语言学
政治学
作者
Dewi Susanti Atmaja,Yulistiani Yulistiani,Suharjono Suharjono,Elida Zairina
标识
DOI:10.1038/s41598-022-17410-w
摘要
Tools to accurately predict and detect adverse drug reactions (ADR) in elderly patients have not been developed. We aimed to identify and evaluate reports on tools that predict and detect ADR in elderly patients (≥ 60 years). In this review, we followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases were searched until January 2022 using key terms "elderly," "adverse drug reaction," and "detection instruments." Eighteen studies met the inclusion criteria, and they examined assorted interventions: STOPP/START version 1/2 (n = 10), Beers Criteria 2012 or 2015 (n = 4), Systematic Tool to Reduce Inappropriate Prescribing (STRIP) (n = 2), Tool to Reduce Inappropriate Medications (TRIM) (n = 1), Medication Risk Score (MERIS) (n = 1), Computerized alert systems (n = 1), and Norwegian General Practice-Nursing Home criteria (n = 1). The interventions affected the number of potential prescription omissions (OR, 0.50 [0.37-0.69]; p < 0.0001; four studies). No apparent reduction in the number of drug interactions within 2 months (OR, 0.84 [0.70-1.02]; p = 0.08; two studies) and mortality (OR, 0.92 [0.76-1.12]; p = 0.41; three studies) was observed. In conclusion, there is no definitive and validated assessment tool for detecting and predicting ADR in elderly patients. Thus, more research on refining existing tools or developing new ones is warranted.
科研通智能强力驱动
Strongly Powered by AbleSci AI